Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
11:20am, Monday, 07'th Mar 2022 Zacks Investment Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
11:20am, Friday, 04'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Neurocrine Biosciences cut to neutral at Piper on growth trajectory of Ingrezza
08:23pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Piper Sandler has downgraded Neurocrine Biosciences (NBIX) to neutral from overweight amid concerns of more modest long-term growth of its tardive dyskinesia treatment Ingrezza.
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
03:03pm, Thursday, 03'rd Mar 2022 Benzinga
Upgrades
For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q
NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day
01:20pm, Monday, 28'th Feb 2022 Zacks Investment Research
NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Neurocrine Biosciences (NBIX)
11:20am, Monday, 28'th Feb 2022 Zacks Investment Research
Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates
Bear of the Day: Neurocrine Biosciences (NBIX)
07:43am, Monday, 28'th Feb 2022
Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates
Where Neurocrine Biosciences Stands With Analysts
07:05pm, Friday, 25'th Feb 2022 Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
4
0
0
Where Neurocrine Biosciences Stands With Analysts
07:05pm, Friday, 25'th Feb 2022 Benzinga
Neurocrine Biosciences (NASDAQ: NBIX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 2 0 0 2M Ago 0 1 2 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $110.75 with a high of $154.00 and a low of $90.00. Below is a summary of how these 8 analysts rated Neurocrine Biosciences over the past … Full story available on Benzinga.com
Neurocrine Biosciences upgraded to buy at Goldman Sachs; sees 32% upside (NBIX)
04:34pm, Friday, 25'th Feb 2022 Seeking Alpha
Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months.
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
03:04pm, Friday, 25'th Feb 2022 Benzinga
Upgrades
According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56, compared to year-ago quarter EPS o
Neurocrine Biosciences Looking At A Year Of Heavy Lifting
04:11pm, Tuesday, 15'th Feb 2022
Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum.
Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript
09:30pm, Friday, 11'th Feb 2022 The Motley Fool
NBIX earnings call for the period ending December 31, 2021.
Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript
09:30pm, Friday, 11'th Feb 2022 The Motley Fool
NBIX earnings call for the period ending December 31, 2021.
